Access & commercial value
Explore a paper’s conversation or start a broader discussion below.
Inclisiran access: the referral queue behind an infrequent injection
A patient-pathway funnel, starter-dose capacity check and financial threshold show why convenient dosing still needs an operating system.
When the Clinical Trial Comes Home
A study visit at the kitchen table could remove a long journey. Good trial design also asks who gains access, who takes on new work, and how the evidence stays dependable.
One Treatment, a Lifetime of Questions
A durable therapy changes more than a treatment schedule. It asks healthcare to think differently about follow-up, evidence, payment, and the years that come after.
The Medicine We Hope Not to Need
A new antibiotic can be most valuable when it is used carefully. That creates a revealing challenge for how we fund discovery, protect effectiveness, and keep treatment available.
Entresto’s lifecycle asks a harder question: where should the field team go next?
Recent generic-pressure reporting anchors a fictional sales-force redeployment and productivity model.
What cardiovascular evidence adds to an access dossier
Wegovy’s outcomes result and Medicare’s next negotiation cycle frame evidence, budget and eligible-population planning.
A price cut needs a volume hurdle and an access diagnosis
Repatha’s historical reset and recent growth provide context for a fictional launch team’s break-even calculation.
After Humira: build a price–volume bridge, not a patent-cliff slogan
Historical U.S. erosion and 2026 global reporting inform a hypothetical biosimilar-response model.
A valuable cure can still create a treatment queue
Sovaldi and current Medicare pricing implementation frame an indication-specific budget-impact assignment.
Measure an advisory engagement by the decision it improves
Define the baseline, deliverables and economic perspective before attributing time or money saved to an intervention.
AI biotech financing: measure the evidence purchased by a larger round
Historical financing events and a runway model clarify what a capital headline can—and cannot—tell a reader.
Metabolic disease: sequence indications around evidence, capacity and access
A MASH case shows why a biomarker result, an approval and a commercial forecast answer different questions.
Women’s health: translating trial response into accessible, durable value
Clinical endpoints, monitoring requirements and patient persistence belong in the same commercial plan.
Drug-development economics: make the assumptions visible
A corrected public cost study shows why a headline R&D estimate is a starting point for analysis, not a universal budget or price justification.
Supply resilience is part of access: reading drug-shortage statistics carefully
Recent FDA prevention counts provide a signal about supply interventions, while leaving product-level access questions unresolved.
Biosimilar access: approval creates an option, implementation creates reach
A record approval year offers an opportunity to examine the operational steps between regulatory entry and patient access.
Amgen v. Sanofi: antibody breadth needs enabling evidence
The 2023 decision puts a measurable boundary around a broad molecular-platform narrative.
Provenge: survival benefit did not remove commercial constraints
Dendreon’s 2010–2014 record separates clinical value, operating revenue, and financing resilience.
Sickle-cell gene therapy: access is an agreement and a care pathway
The CMS access model makes outcome contracting, treatment logistics, and follow-up separate milestones.
Discussion
Share evidence, ask a question, or offer a professional perspective. Community guidelines
Loading discussion…